The agency approved Roche’s Vabysmo to treat neovascular or “wet” age-related macular degeneration and diabetic macular edema.
Roche announced on Jan. 31, 2022 that FDA approved Vabysmo (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME). The bispecific antibody targets and inhibits two disease pathways that are linked to vision loss by neutralizing angiopoietin-2 and vascular endothelial growth factor-A.
The FDA approval is based on results from four Phase III studies that showed patients given the drug at intervals up to four months had “non-inferior vision gains versus aflibercept given every two months in the first year.” Patients with either nAMD or DME would receive four monthly treatments and may need additional treatments based on treatment outcomes. “A second approved treatment regimen for DME involves six monthly loading doses, followed by treatment every two months. Some people with nAMD and DME may be treated monthly if needed, although additional efficacy was not demonstrated in most people given Vabysmo every month,” the company stated in a press release.
“Vabysmo provides a new approach to treating vision-threatening retinal conditions through a mechanism of action that targets two pathways simultaneously,” said Levi Garraway, M.D., PhD, Roche’s Chief Medical Officer and Head of Global Product Development, in the press release. “This is our second FDA approval in ophthalmology in recent months, underscoring our commitment to people living with retinal conditions.”
Source: Roche
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.